Biogen | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
ALKERMES USD 2.08B 26.41M 2025-03
Amgen USD 89.37B 2.47B 2025-03
Bayer EUR 110.85B 3.9B 2024-12
Biogen USD 28.03B 16.2M 2025-03
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Eli Lilly USD 89.39B 10.67B 2025-03
Gilead Sciences USD 56.43B 2.56B 2025-03
Incyte USD 5.75B 305.04M 2025-03
Merck USD 115.12B 1.98B 2025-03
Moderna USD 12.7B 1.44B 2025-03
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 208.03B 5.37B 2025-03
PTC Therapeutics USD 1.71B 137.21M 2024-12
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Sanofi 131.89B 906M 2025-03
Sanofi 132.8B 3.04B 2024-12
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
Teva Pharmaceutical Industries USD 39.33B 2.43B 2024-12
Ultragenyx Pharmaceutical USD 1.5B 34.91M 2024-12
United Therapeutics USD 7.74B 379.9M 2025-03
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Biogen Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.